William Lasswell, MD
Endocrinology, Diabetes & Metabolism · Vero Beach, FLNPI 1093898546
Payments from drug & device makers
Across 220 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$795
- Novo Nordisk$552
- AstraZeneca$457
- Boehringer Ingelheim$432
- Lilly USA, LLC$309
- Bayer$289
- plus $934 from 17 others
What the payments were for
- Food & beverage$3,760100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 43 | $795 |
| Novo Nordisk | 42 | $552 |
| AstraZeneca | 29 | $457 |
| Boehringer Ingelheim | 23 | $432 |
| Lilly USA, LLC | 18 | $309 |
| Bayer | 14 | $289 |
| Abbott | 7 | $145 |
| Dexcom, Inc. | 6 | $102 |
| Radius Health, Inc. | 5 | $94 |
| Insulet Corporation | 4 | $84 |
| Medtronic(2 entities) | 4 | $69 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Amgen | 4 | $65 |
| Johnson & Johnson | 3 | $56 |
| AbbVie | 3 | $52 |
| Merck | 3 | $41 |
| Amarin Pharma, Inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $37 |
| BD | 1 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Vivus LLC | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Valeritas, Inc. | 1 | $13 |
How this compares
$3,768 in reported general payments places this provider in the 45th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 22 | $387 |
| Metformin Hcl | 11 | $69 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Vero Beach
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.